FDA Approves Merck’s Sotatercept-csrk for PAH Treatment: A New Era in Pulmonary Hypertension Therapy
Source-fiercepharma Sotatercept’s Approval Marks a Milestone in Pulmonary Arterial Hypertension (PAH)Treatment On March 26th, the US FDA granted approval for Merck’s WINREVAIR™ (sotatercept-csrk), a significant advancement in the treatment of pulmonary arterial hypertension (PAH). PAH, a condition characterized by elevated blood pressure in the arteries connecting the heart and lungs, poses a serious risk of heart failure. While existing pulmonary vasodilators have improved patient outcomes, the challenge of disease progression persists, highlighting the need for innovative treatments like Sotatercept. Understanding Sotatercept’s Mechanism of Action Sotatercept introduces a novel approach to pulmonary arterial hypertension (PAH) therapy . Acting as a fusion protein, it incorporates the binding site of ACVR2A, disrupting downstream signaling pathways, particularly the SMAD pathway. By sequestering activin, a member of the TGF-β superfamily, Sotatercept restores the bal...